
developing and testing new Hepatitis C drug treatments lately, investors may find it difficult to keep up. Idenix Pharmaceuticals ( IDIX ) recently revealed some promising news concerning clinical trials for one of its new Hepatitis C drug treatments
Idenix Pharmaceuticals , Inc. ( IDIX ) Deutsche Bank 37th Annual Healthcare Conference Call May ..... Presentation Robyn Karnauskas – Deutsche Bank Next we have Idenix Pharmaceuticals , and we have the President and CEO, Ron Renaud, future
By Ganaxi Small Cap Movers : Switzerland-based BB Biotech, founded in 1993, is one of the largest pure-play biotech investment companies, and also a public company with its shares are listed on the Swiss Stock Market. About a third of its assets are invested in oncology-focused biotech companies,
By Vatalyst : Buyout and takeover news usually rocks the market, and the potential changes concerning Human Genome Sciences ( HGSI ) and GlaxoSmithKline ( GSK ) are no exception. Human Genome Sciences rejected the takeover bid, creating a bit of uncertainty for itself. The two companies have worked
By ValueMax : Spectrum Pharmaceuticals ( SPPI ) has always been one of my favorite options in the biotech industry and it has lately begun getting attention from some of the experts. The thing people seem to like about this company is its blend of research and development, mixed with a strong plan
By Stock Croc : Finding the right biotech stock is a challenge because there are so many choices. You need to evaluate your priorities and, perhaps most importantly, your budget. There are options in all price categories, but in many cases you get what you pay for. There are some low-cost options
Idenix Pharmaceuticals ( IDIX +6.5% ) jumps on an upgrade to Market Perform on valuation at JMP Securities, citing its emerging pipeline. Post your comment!
By Mel Daris : Spectrum Pharmaceuticals ( SPPI ) , a biotech, research and development company, keeps one eye firmly focused on commercialization of its products and the other on retaining a continual, positive cash flow. On the surface, the company seems to have "bet the entire store": cancer ...
By Ry Frank : I believe the best investments in the biotech market are in companies focused on the treatment of chronic diseases. There are many people suffering from diseases for which there are no cures, but medical science has developed ways to manage these illnesses and make it possible to live
By Mel Daris : When a company like Abbott Laboratories ( ABT ) frequently makes the news, it is not necessarily a good thing. Breakthrough pharmaceuticals take a long time to develop, so it is not uncommon to have long periods without any news. Abbott Laboratories is not in this rut currently, as